title: Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
abstract: 4-Amino- and 4-guanidino-4H-pyran-6-carboxamides 4 and 5 related to zanamivir (GG167) are a new class of inhibitors of influenza virus sialidases. Structure--activity studies reveal that, in general, secondary amides are weak inhibitors of both influenza A and B viral sialidases. However, tertiary amides, which contain one or more small alkyl groups, show much greater inhibitory activity, particularly against the influenza A virus enzyme. The sialidase inhibitory activities of these compounds correlate well with their in vitro antiviral efficacy, and several of the most potent analogues displayed useful antiviral activity in vivo when evaluated in a mouse model of influenza A virus infection. Carboxamides which were highly active sialidase inhibitors in vitro also showed good antiviral activity in the mouse efficacy model of influenza A infection when administered intranasally but displayed modest activity when delivered by the intraperitoneal route.
authors.affiliation: Department of Enzyme Medicinal Chemistry, Glaxo Wellcome Research and Development Limited, Stevenage, Herts, U.K.
authors.forename: P W
authors.initials: PW
authors.lastname: Smith
authors.forename: S L
authors.initials: SL
authors.lastname: Sollis
authors.forename: P D
authors.initials: PD
authors.lastname: Howes
authors.forename: P C
authors.initials: PC
authors.lastname: Cherry
authors.forename: I D
authors.initials: ID
authors.lastname: Starkey
authors.forename: K N
authors.initials: KN
authors.lastname: Cobley
authors.forename: H
authors.initials: H
authors.lastname: Weston
authors.forename: J
authors.initials: J
authors.lastname: Scicinski
authors.forename: A
authors.initials: A
authors.lastname: Merritt
authors.forename: A
authors.initials: A
authors.lastname: Whittington
authors.forename: P
authors.initials: P
authors.lastname: Wyatt
authors.forename: N
authors.initials: N
authors.lastname: Taylor
authors.forename: D
authors.initials: D
authors.lastname: Green
authors.forename: R
authors.initials: R
authors.lastname: Bethell
authors.forename: S
authors.initials: S
authors.lastname: Madar
authors.forename: R J
authors.initials: RJ
authors.lastname: Fenton
authors.forename: P J
authors.initials: PJ
authors.lastname: Morley
authors.forename: T
authors.initials: T
authors.lastname: Pateman
authors.forename: A
authors.initials: A
authors.lastname: Beresford
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D006146:Guanidines / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D009980:Influenza A virus / Q000187:drug effects* / Q000201:enzymology; D009981:Influenza B virus / Q000187:drug effects* / Q000201:enzymology; D007274:Injections, Intraperitoneal; D051379:Mice; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000201:enzymology; D011714:Pyrans / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D012794:Sialic Acids / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D053243:Zanamivir
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir